Tivozanib Hydrochloride Rollover Protocol(Continued Access)
Research type
Research Study
Full title
A Rollover Protocol to Allow Continued Access to Tivozanib Hydrochloride (AV-951) for Subjects Enrolled in Other Tivozanib Hydrochloride Protocols
IRAS ID
124356
Contact name
Tim Eisen
Contact email
Sponsor organisation
AVEO Pharmaceuticals, Inc.
Eudract number
2009-013407-66
ISRCTN Number
n.a
Clinicaltrials.gov Identifier
n.a
Research summary
This is a rollover protocol for participants who have previously taken part in other tivozanib hydrochloride studies, to allow patients to continue treatment with tivozanib hydrochloride if they are tolerating the study drug and benefiting from the treatment.
REC name
East of England - Cambridge East Research Ethics Committee
REC reference
13/EE/0077
Date of REC Opinion
22 May 2013
REC opinion
Further Information Favourable Opinion